tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matt Hewitt, 86 are a BUY (82.69%), 17 are a HOLD (16.35%), 1 are a SELL (0.96%).
Analyst Matt Hewitt, currently employed at CRAIG HALLUM, carries an average stock price target met ratio of 49.5% that have a potential upside of 28.8% achieved within 141 days.
Matt Hewitt’s has documented 227 price targets and ratings displayed on 18 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on LGND, Ligand Pharmaceuticals orporated at 09-Jul-2024.
Analyst best performing recommendations are on TDOC (TELADOC).
The best stock recommendation documented was for TDOC (TELADOC) at 2/23/2022. The price target of $67 was fulfilled within 1 day with a profit of $5.54 (9.01%) receiving and performance score of 90.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
8
$-1.45 (-15.34%)
8
23 days ago
8/12 (66.67%)
$0.3 (3.90%)
32
Buy
14
$4.55 (48.15%)
20
7 months 18 days ago
5/6 (83.33%)
$9.36 (201.72%)
59
Buy
16
$7.76 (94.17%)
22
7 months 18 days ago
2/6 (33.33%)
$11.36 (244.83%)
266
Buy
20
$11.76 (142.72%)
22
1 years 1 months 4 days ago
1/4 (25%)
$6.26 (45.56%)
92
Buy
9
$-0.45 (-4.76%)
11
4 years 4 months 15 days ago
3/3 (100%)
$4.49 (99.56%)
356
Which stock is Matt Hewitt is most bullish on?
Which stock is Matt Hewitt is most reserved on?
What Year was the first public recommendation made by Matt Hewitt?
